Holders — by stockHoldings — by fund
Versant Venture Management, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001560009
$162.6M
disclosed book value
8
positions
47.3%
largest position share
Positions, as of 2026-06-30
top 8 of 8 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | GLUEMonte Rosa Therapeutics, Inc. | 3.2M | $77.0M | 47.3% |
| 2 | IPSCCentury Therapeutics, Inc. | 12.2M | $29.8M | 18.3% |
| 3 | JBIOJade Biosciences, Inc. | 991,783 | $22.0M | 13.6% |
| 4 | LENZLenz Therapeutics, Inc. | 2.7M | $15.1M | 9.3% |
| 5 | CTNMContineum Therapeutics, Inc. | 542,628 | $8.9M | 5.5% |
| 6 | CRISPR Therapeutics AG | 148,831 | $8.1M | 5% |
| 7 | SKYESkye Bioscience, Inc. | 2.0M | $1.4M | 0.9% |
| 8 | OVASUSDTempest Therapeutics, Inc. | 269,772 | $299,447 | 0.2% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.